{"transactions":[{"id":4635396,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-10-01T17:19:28.000Z","date":"2026-09-30","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":37.38,"value":1121400.0,"ownership":{"direct":true},"balance_after":49923,"source":{"system":"sec-edgar","filing":"0001193125-26-409999","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526409999/ownership.xml","form_type":"4"}},{"id":843544,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Restricted Share Units","published_at":"2026-03-14T00:16:26.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":37500,"derivative":{"underlying":"Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-26-106724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526106724/ownership.xml","form_type":"4"}},{"id":843543,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:26.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":7308,"price":55.225,"value":403584.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025."}],"balance_after":19923,"source":{"system":"sec-edgar","filing":"0001193125-26-106724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526106724/ownership.xml","form_type":"4"}},{"id":843542,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-14T00:16:26.000Z","date":"2026-03-12","kind":"exercise","planned":true,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares earned and vested under a restricted share unit (\"RSU\") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":27231,"source":{"system":"sec-edgar","filing":"0001193125-26-106724","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526106724/ownership.xml","form_type":"4"}},{"id":848237,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848236,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Performance Share Units","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"grant","planned":true,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"shares","element":"transactionShares","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":20000,"derivative":{"underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848235,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.44,"expiration_date":"2029-09-15","underlying":"Common Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848234,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":4.75,"expiration_date":"2028-03-11","underlying":"Common Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848233,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2027-10-22","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848232,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.4,"expiration_date":"2027-03-12","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848231,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":11269,"price":60.108,"value":677357.052,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024."}],"balance_after":14731,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848230,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents shares earned and vested under a performance share unit (\"PSU\") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination."}],"balance_after":26000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848229,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":65000,"price":62.06,"value":4033900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848228,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":65000,"price":9.44,"value":613600.0,"ownership":{"direct":true},"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848227,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":61652,"price":60.08,"value":3704052.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.75 to $60.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848226,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":43348,"price":59.26,"value":2568802.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.745 to $59.735, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":72652,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848225,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":105000,"price":4.75,"value":498750.0,"ownership":{"direct":true},"balance_after":111000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848224,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":2449,"price":61.26,"value":150025.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $61.055 to $61.555, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848223,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":10072,"price":60.47,"value":609053.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.05 to $61.035, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":8449,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848222,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":12479,"price":59.5,"value":742500.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.03 to $60.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":18521,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848221,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":3.1,"value":77500.0,"ownership":{"direct":true},"balance_after":31000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848220,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":21515,"price":60.49,"value":1301442.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $60.16 to $61.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848219,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":31694,"price":59.88,"value":1897836.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $59.16 to $60.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":27515,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848218,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":21791,"price":58.81,"value":1281528.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, or shares sold. These shares were sold in multiple transactions at prices ranging from $58.16 to $59.1425, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":59209,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":848217,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-03-11T23:20:23.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":75000,"price":8.4,"value":630000.0,"ownership":{"direct":true},"balance_after":81000,"source":{"system":"sec-edgar","filing":"0001193125-26-102666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526102666/ownership.xml","form_type":"4"}},{"id":941833,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Restricted Share Units","published_at":"2026-01-09T23:51:00.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027."}],"balance_after":65000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001193125-26-009230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526009230/ownership.xml","form_type":"4"}},{"id":941832,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Share Option (Right to Buy)","published_at":"2026-01-09T23:51:00.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":350000,"derivative":{"exercise_price":42.15,"expiration_date":"2036-01-08","underlying":"Common Shares","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-26-009230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526009230/ownership.xml","form_type":"4"}},{"id":954889,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.49,"expiration_date":"2026-03-10","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":954888,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":2062,"price":44.93,"value":92645.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $44.91 to $45.125, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":954887,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":37938,"price":44.4,"value":1684447.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $43.91 to $44.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":8062,"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":954886,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2026-01-02T23:49:48.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":7.49,"value":299600.0,"ownership":{"direct":true},"balance_after":46000,"source":{"system":"sec-edgar","filing":"0001193125-26-001172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312526001172/ownership.xml","form_type":"4"}},{"id":975570,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-10T00:40:08.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":2010,"price":46.32,"value":93103.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.02 to $46.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001193125-25-313147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525313147/ownership.xml","form_type":"4"}},{"id":975569,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-10T00:40:08.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":8820,"price":45.59,"value":402103.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $45.02 to $46.013, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":8010,"source":{"system":"sec-edgar","filing":"0001193125-25-313147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525313147/ownership.xml","form_type":"4"}},{"id":975568,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-10T00:40:08.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":14375,"price":45.03,"value":647306.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $45.00 to $45.135, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":16830,"source":{"system":"sec-edgar","filing":"0001193125-25-313147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525313147/ownership.xml","form_type":"4"}},{"id":981095,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-12-04T01:20:44.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":97,"price":45.01,"value":4365.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."}],"balance_after":31205,"source":{"system":"sec-edgar","filing":"0001193125-25-307211","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525307211/ownership.xml","form_type":"4"}},{"id":1029066,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO & INTERIM CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-01T23:17:11.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.69,"expiration_date":"2025-12-17","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-227202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525227202/ownership.xml","form_type":"4"}},{"id":1029065,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO & INTERIM CFO"}}],"security":"Common Shares","published_at":"2025-10-01T23:17:11.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":40.16,"value":1004000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.495, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0001193125-25-227202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525227202/ownership.xml","form_type":"4"}},{"id":1029064,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT, CEO & INTERIM CFO"}}],"security":"Common Shares","published_at":"2025-10-01T23:17:11.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":7.69,"value":192250.0,"ownership":{"direct":true},"balance_after":56302,"source":{"system":"sec-edgar","filing":"0001193125-25-227202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525227202/ownership.xml","form_type":"4"}},{"id":1207424,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Restricted Share Units","published_at":"2025-03-13T23:33:34.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026."}],"balance_after":50000,"derivative":{"exercise_price":0,"underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-25-039025","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025039025/ownership.xml","form_type":"4"}},{"id":1207423,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Share Option (Right to Buy)","published_at":"2025-03-13T23:33:34.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":275000,"derivative":{"exercise_price":35.48,"expiration_date":"2035-03-11","underlying":"Common Shares","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000950170-25-039025","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025039025/ownership.xml","form_type":"4"}},{"id":1294273,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-27","kind":"exercise","planned":true,"acquired":false,"shares":16315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.76,"expiration_date":"2025-03-16","underlying":"Common Shares","underlying_shares":16315},"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294272,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-24","kind":"exercise","planned":true,"acquired":false,"shares":22468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":16315,"derivative":{"exercise_price":17.76,"expiration_date":"2025-03-16","underlying":"Common Shares","underlying_shares":22468},"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294271,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-23","kind":"exercise","planned":true,"acquired":false,"shares":16217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":38783,"derivative":{"exercise_price":17.76,"expiration_date":"2025-03-16","underlying":"Common Shares","underlying_shares":16217},"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294270,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":1149,"price":41.07,"value":47189.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $41.01 to $41.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294269,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-27","kind":"exercise","planned":true,"acquired":true,"shares":1149,"price":17.76,"value":20406.24,"ownership":{"direct":true},"balance_after":32451,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294268,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":15166,"price":40.46,"value":613616.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294267,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-27","kind":"exercise","planned":true,"acquired":true,"shares":15166,"price":17.76,"value":269348.16,"ownership":{"direct":true},"balance_after":46468,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294266,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-24","kind":"sale","planned":true,"acquired":false,"shares":22468,"price":40.2,"value":903213.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.535, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294265,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-24","kind":"exercise","planned":true,"acquired":true,"shares":22468,"price":17.76,"value":399031.68,"ownership":{"direct":true},"balance_after":53770,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294264,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-23","kind":"sale","planned":true,"acquired":false,"shares":16217,"price":40.08,"value":649977.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $40.00 to $40.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1294263,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2025-01-28T01:28:53.000Z","date":"2025-01-23","kind":"exercise","planned":true,"acquired":true,"shares":16217,"price":17.76,"value":288013.92,"ownership":{"direct":true},"balance_after":47519,"source":{"system":"sec-edgar","filing":"0000950170-25-009388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017025009388/ownership.xml","form_type":"4"}},{"id":1580191,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-12T22:33:15.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":250000,"derivative":{"exercise_price":44.37,"expiration_date":"2034-03-10","underlying":"Common Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-24-030226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017024030226/ownership.xml","form_type":"4"}},{"id":1875994,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"exercise","planned":false,"acquired":false,"shares":6172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock\nSplit. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.85,"expiration_date":"2024-01-13","underlying":"Common Shares","underlying_shares":6172},"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875993,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"exercise","planned":false,"acquired":false,"shares":20576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock\nSplit. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.85,"expiration_date":"2024-01-13","underlying":"Common Shares","underlying_shares":20576},"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875992,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"exercise","planned":false,"acquired":false,"shares":42592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the \"Reverse Stock Split\"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":9.44,"expiration_date":"2023-07-31","underlying":"Common Shares","underlying_shares":42592},"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875991,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"sale","planned":false,"acquired":false,"shares":1407,"price":41.49,"value":58376.43,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":31302,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875990,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":1171,"price":41.84,"value":48994.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations."}],"balance_after":32709,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875989,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"exercise","planned":false,"acquired":true,"shares":6172,"price":9.85,"value":60794.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock\nSplit. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":33880,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875988,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"sale","planned":false,"acquired":false,"shares":13179,"price":41.37,"value":545215.23,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":27708,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875987,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":3902,"price":41.84,"value":163259.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations."}],"balance_after":40887,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875986,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"exercise","planned":false,"acquired":true,"shares":20576,"price":9.85,"value":202673.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock\nSplit. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":44789,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875985,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"sale","planned":false,"acquired":false,"shares":17069,"price":41.44,"value":707339.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The \"Amount\" and \"Price\" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."}],"balance_after":24213,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875984,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":7310,"price":41.84,"value":305850.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations."}],"balance_after":41282,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1875983,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Shares","published_at":"2023-05-26T23:10:49.000Z","date":"2023-05-24","kind":"exercise","planned":false,"acquired":true,"shares":42592,"price":9.44,"value":402068.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the \"Reverse Stock Split\"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise."}],"balance_after":48592,"source":{"system":"sec-edgar","filing":"0000950170-23-024600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023024600/ownership.xml","form_type":"4"}},{"id":1953569,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-14T20:36:15.000Z","date":"2023-03-10","kind":"grant","acquired":true,"shares":380000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":380000,"derivative":{"exercise_price":34.18,"expiration_date":"2033-03-09","underlying":"Common Shares","underlying_shares":380000},"source":{"system":"sec-edgar","filing":"0001209191-23-018482","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919123018482/doc4.xml","form_type":"4"}},{"id":2334879,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-14T20:15:42.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":400000,"derivative":{"exercise_price":30.01,"expiration_date":"2032-03-09","underlying":"Common Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-22-018453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919122018453/doc4.xml","form_type":"4"}},{"id":2682349,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T20:46:06.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% on the first anniversary of June 3, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":125000,"derivative":{"exercise_price":18.56,"expiration_date":"2031-06-02","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-21-037707","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121037707/doc4.xml","form_type":"4"}},{"id":2788740,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-15T20:37:56.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":100000,"derivative":{"exercise_price":20.55,"expiration_date":"2031-03-11","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-21-020476","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919121020476/doc4.xml","form_type":"4"}},{"id":3210389,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-13T21:03:21.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":145000,"derivative":{"exercise_price":11.58,"expiration_date":"2030-03-11","underlying":"Common Shares","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001209191-20-018951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919120018951/doc4.xml","form_type":"4"}},{"id":3410488,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T22:47:50.000Z","date":"2019-09-16","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting over 36 months, in equal amounts, on the last day of each month."}],"balance_after":135000,"derivative":{"exercise_price":9.44,"expiration_date":"2029-09-15","underlying":"Common Shares","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-19-050143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000120919119050143/doc4.xml","form_type":"4"}},{"id":3997564,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-13T21:42:04.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":105000,"derivative":{"exercise_price":4.75,"expiration_date":"2028-03-11","underlying":"Common Shares","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001171843-18-001914","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184318001914/form4.xml","form_type":"4"}},{"id":4181062,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-24T22:48:53.000Z","date":"2017-10-23","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":25000,"derivative":{"exercise_price":3.1,"expiration_date":"2027-10-22","underlying":"Common Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001171843-17-006258","document":"form4mortimer.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317006258/form4mortimer.xml","form_type":"4"}},{"id":4234983,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Common Stock","published_at":"2017-08-14T22:07:28.000Z","date":"2017-08-10","kind":"purchase","acquired":true,"shares":10000,"price":2.9,"value":29000.0,"ownership":{"direct":false,"nature":"By Spouse"},"balance_after":14300,"source":{"system":"sec-edgar","filing":"0001171843-17-005071","document":"f4_mortimer081417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317005071/f4_mortimer081417.xml","form_type":"4"}},{"id":4234982,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Common Stock","published_at":"2017-08-14T22:07:28.000Z","date":"2017-08-10","kind":"purchase","acquired":true,"shares":5000,"price":2.845,"value":14225.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001171843-17-005071","document":"f4_mortimer081417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317005071/f4_mortimer081417.xml","form_type":"4"}},{"id":4385913,"issuer":{"id":2602,"kind":"organization","name":"Xenon Pharmaceuticals Inc.","symbol":"XENE"},"owners":[{"id":60928,"kind":"person","name":"MORTIMER IAN","position":1,"cik":"0001619961","reported_name":"MORTIMER IAN","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-14T20:26:04.000Z","date":"2017-03-13","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month."}],"balance_after":75000,"derivative":{"exercise_price":8.4,"expiration_date":"2027-03-12","underlying":"Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001171843-17-001506","document":"formfour.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582313/000117184317001506/formfour.xml","form_type":"4"}}]}